Get the Stockscreener App
40.61
4.29%
-1.82
Pre-market:
40.61
Agios Pharmaceuticals Inc stock is traded at $40.61, with a volume of 657.57K.
It is down -4.29% in the last 24 hours and up +13.82% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$42.43
Open:
$42.51
24h Volume:
657.57K
Relative Volume:
0.85
Market Cap:
$2.36B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.5748
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+0.27%
1M Performance:
+13.82%
6M Performance:
+60.45%
1Y Performance:
-2.89%
1-Day Range:
$40.20
$42.51
1-Week Range:
$40.20
$43.21
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
40.61 | 2.47B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsProduct Launch & Fast Exit and Entry Strategy Plans - newser.com
What to expect from Agios Pharmaceuticals Inc. in the next 30 daysTrade Exit Summary & Weekly High Potential Alerts - newser.com
How Agios Pharmaceuticals Inc. stock reacts to bond yieldsWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Will Agios Pharmaceuticals Inc. continue its uptrendJuly 2025 Decliners & Weekly Top Performers Watchlists - newser.com
Will Agios Pharmaceuticals Inc. see short term momentumMarket Activity Report & Low Risk Profit Maximizing Plans - newser.com
Has Agios Pharmaceuticals Inc. formed a bullish divergence2025 Year in Review & Daily Stock Trend Reports - newser.com
Why Agios Pharmaceuticals Inc. (8AP) stock gets analyst attentionJuly 2025 Retail & Risk Managed Investment Signals - newser.com
Zacks Research Issues Pessimistic Outlook for AGIO Earnings - MarketBeat
Will Agios Pharmaceuticals Inc. outperform the marketForecast Cut & AI Forecast for Swing Trade Picks - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock outperform Dow JonesPortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Analyzing recovery setups for Agios Pharmaceuticals Inc. investorsJuly 2025 Catalysts & Smart Allocation Stock Reports - newser.com
How to use a screener to detect Agios Pharmaceuticals Inc. breakoutsWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com
Using R and stats models for Agios Pharmaceuticals Inc. forecasting2025 Trading Volume Trends & Weekly High Return Stock Opportunities - newser.com
Relative strength of Agios Pharmaceuticals Inc. in sector analysisTrade Volume Report & Scalable Portfolio Growth Methods - newser.com
Leading vs lagging indicators on Agios Pharmaceuticals Inc. performanceWeekly Trade Review & Safe Entry Trade Signal Reports - newser.com
Agios Pharmaceuticals' (AGIO) Hold (C-) Rating Reiterated at Weiss Ratings - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to "Strong Sell" at Zacks Research - MarketBeat
Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Will Agios Pharmaceuticals Inc. stock benefit from commodity prices2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - Eastern Progress
What momentum shifts mean for Agios Pharmaceuticals Inc.July 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Is Agios Pharmaceuticals Inc. reversing from oversold territoryQuarterly Trade Summary & Free Verified High Yield Trade Plans - newser.com
Published on: 2025-10-02 19:48:50 - newser.com
Agios Pharmaceuticals Hits Day High with 9.64% Surge in Stock Price - Markets Mojo
Published on: 2025-10-01 06:17:51 - newser.com
Agios Pharmaceuticals Inc Stock Analysis and ForecastDividend Yield Trends & Rapid Portfolio Trading Growth - earlytimes.in
Beta Thalassemia Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Agios Pharma, Vertex Pharma, Pharmacosmos, Editas Medicine, HemaQuest Pharma Q, Acceleron Pharma - Barchart.com
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scadden David | Director |
Oct 08 '25 |
Sale |
41.00 |
200 |
8,200 |
17,603 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):